Al Sandrock, the top scientist at Biogen who exited last year in a dispute over its controversial Alzheimer’s treatment, has landed a new job as the CEO of Voyager Therapeutics, the company said Tuesday.
Voyager’s appointment of Sandrock as its new CEO is the latest in a series of moves aimed at refocusing the company on a new gene therapy delivery technology, following setbacks with its earlier pipeline.